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Epilepsy is the most common worldwide neurologic
disorder amenable to treatment, if not cure, provided
treatment is initiated early and continuously monitored
(1). This is feasible in developed countries with their
national wealth, organized health care, and availability of
health insurance for all. The quality health care includes
the all-important critical care medicine and facilities for
rehabilitation.
GROUND REALITIES
The situation in developing nations is widely different,
with available care of varying standards. Each develop-
ing country has its own national priorities, and generally,
health is low in the list. Even here, communicable dis-
eases and other health programs head the list, and epi-
lepsy is nowhere in the horizon. We have failed to lobby
repeatedly that epilepsy is not a mental illness requiring
life-long medication and that in a vast majority, it can be
treated effectively to lead to a perfectly normal life and
contribute to national productivity and wealth.
Even in the year 2000, India continued to live in vil-
lages. Seventy percent of the population is rural, whereas
70% of the medical manpower is urban—the distribution
is thus skewed. Prevalence of active epilepsy in India is
∼5 per 1,000 in a population of 1 billion. Specialists in
neurology total ∼500, amounting to 1 for 10,000 subjects
with active epilepsy. They are all urban based, as are the
tools for investigations, some of which are highly expen-
sive. Facilities for critical care medicine and rehabilita-
tion exist only in large cities. Health insurance is
specifically denied for epilepsy. Hence quality health
care is but a distant dream except for a lucky few in rural
India.
RURAL POOR
The rural poor must depend on the poorly managed
governmental Primary Health Units and Centers, besides
the private practitioner or alternate systems of medicine.
Only phenobarbitone (PB) and phenytoin (PHT) are af-
fordable, and in the absence of health education, com-
pliance with drug regimens is rare. When the response is
poor, which is common, a minority attend metropolitan
centers, but become disillusioned quickly because the
antiepileptic drug (AED) dose must be tailored to indi-
vidual needs, necessitating frequent follow-up visits and
expense, an impractical situation. Thus, early and effec-
tive treatment, the core of epilepsy control, is not avail-
able for vast majority. The result is uncontrolled epilepsy
with its own inherent risks and impact on the quality of
life.
The best option in such circumstances is to use the
services of trained primary care physicians (PCPs) and
paramedical workers (PMWs) and aim at early treatment
with PB/PHT with limited investigations, but strict
follow-up and health education. This approach has been
advocated before (2,3).
THE YELANDUR MODEL
Our experience with a 5-year follow-up of cases
treated with PB/PHT in Yelandur in South Karnataka
offers additional evidence (4). The Indian Epilepsy As-
sociation, Bangalore chapter, teamed up with Karuna
Trust, a nongovernmental organization (NGO) in Yelan-
dur taluk, for rural epilepsy control. Trained PMWs sur-
veyed a population of 64,963 individuals in 13,562
households for epilepsy using a door-to-door method (5).
Those suspected to have epilepsy were invited to attend
the epilepsy clinic at Yelandur, managed by trained PCPs
and supervised by a team of six specialists, including
three neurologists, all from Bangalore. Here the diagno-
sis, follow-up, drug dosage, and adverse effects were
monitored and supplemented with health education. This
included not only drug and life-style compliance, but
also inculcated a positive approach to epilepsy in terms
of what can be achieved, not what cannot.
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Partial and/or generalized tonic–clonic seizures
(GTCSs) account for 85% of all seizure types in epi-
lepsy, with substantial morbidity and mortality. One hun-
dred eighty-five subjects were recruited for therapy with
inexpensive PB/PHT with a 5-year follow-up. They had
at least two seizures (partial or generalized) in the pre-
vious 1 year and were free of clinical evidence of pro-
gressive neurologic disease at entry or follow-up.
Seventy-five (56%) had a lifetime total (LTT) of >30
GTCSs, and 29 (22%), evidence of brain damage in the
form of mental/neurologic handicap. Subjects with ab-
sence or myoclonic seizures, for which PB/PHT are in-
effective, were not included. Informed consent was
obtained from all patients, and their right to opt out of the
study was respected throughout. Treatment gap at entry
was partial in 36%, absolute in another 43%, and only
21% were taking regular AEDs. Depending on elimina-
tion half-lives for PB/PHT, drug compliance was deemed
present when the number of missed doses per year did
not exceed six. It must be noted that this was not a
randomized study comparing the efficacy of PB and
PHT. The PMWs helped the patients to maintain a sei-
zure calendar and ascertained the number of missed
doses at every home visit, counterchecked by the medical
team during the clinic visits. After an initial stabilization
period of 3 months, patients were offered either PB or
PHT as monotherapy to be taken once daily at night
under supervision. In general, PB was the first drug, and
PHT was reserved for cases showing poor response at
entry to regular PB from elsewhere. Where one drug
failed, the other was substituted slowly, and when both
were ineffective, dual therapy was resorted to. Ulti-
mately PB was used in 68, PHT in 60, and both in seven.
The patients were generally short and thin. The doses
used were far below those generally advocated in the
west or even North India. The per diem dose of PB
generally did not exceed 45 mg in children and 90 mg in
adults, whereas for PHT, the corresponding figures were
150 and 250 mg, respectively. Drug compliance was
67% at 1 year, but thanks to the PMWs, improved to 80,
82, 83, and 84% at each successive follow-up year. The
only option for emergencies was oral/rectal diazepam
(DZP) solution meant for parenteral use. The specialists
verified all data. The study was entirely clinical, because
facilities for investigations did not exist.
Analysis of the results was by intention to treat. The
outcome measure used was complete remission of all
seizure types for 2 years. Patients were divided into
two groups. Group I comprised those with a LTT of30
GTCSs and good drug compliance. Group II did not have
both. A terminal remission of 2 years was seen in 58, 63,
67, and 66%, respectively, at each successive follow-up
year from the second to the fifth. The corresponding
figures for group II were 6, 16, 8, and 8%, respectively,
the differences being statistically significant. Stepwise
multiple logistic regression analysis was used to arrive at
predictors of the outcome measure among the following
eight clinical variables: gender, age at onset, duration of
illness, brain damage, LTT of GTCSs (cut-off point at
30), log of monthly seizure frequency (because of large
variations in distribution), assigned drug, and compli-
ance. Only drug compliance and LTT of 30 GTCSs
turned out to be significant predictors. There was not a
single instance of death of status epilepticus in a drug-
compliant patient and without brain damage. Status was
no more frequent with PB compared with PHT in this
small series.
Clinical adverse effects with PB were noted in only
three (4%) instances and consisted of dullness, hyperki-
nesis, and somnolence in one each, the last opting for
withdrawal from the study. However, adverse effects
were noted in 29 (43%) taking PHT: gingival hyperplasia
in 24 (36%), ataxia in eight (12%), and both in 3 (5%).
Swelling of the gum margins was dependent on dose and
duration of exposure and, most important, oral hygiene,
which is abysmally poor in rural people. Only three sub-
jects withdrew from the study because of adverse effects
with PHT: one with gingival hyperplasia and two with
ataxia.
PRACTICAL LESSONS
What are the lessons from this study? Inexpensive
PB/PHT minus investigations is quite effective in rural
epilepsy control, especially in partial and/or GTCSs, and
without the risk of significant adverse effects. We must
therefore learn to individualize and not to generalize.
Trained PCPs and PMWs can manage this, with a spe-
cialist available for help. For 3 years, the local NGO has
been running an epilepsy clinic every week, attracting
more patients. This approach has helped to establish faith
in the rural folk that effective therapy for epilepsy with
inexpensive drugs is possible at their doorstep. This is a
practical proposition in India and possibly other devel-
oping countries with existing resources. All it needs is a
sense of commitment and missionary zeal. The essential
prerequisites are trained PCPs and PMWs, the latter pref-
erably from the local population; use of inexpensive
AEDs; an unbroken drug chain; regular follow-up; and
persistent health education. The neurologic fraternity in
the country has been repeatedly addressed about revision
of the curriculum on epilepsy for the undergraduates (6).
Concurrent steps are also being initiated for training in
practical epileptology for PCPs and health workers in
Karnataka and other states. We always hope that some-
thing tangible will emerge.
“Does epilepsy need exclusive diagnosis and treat-
ment facilities? Clearly not” (7). It is not justifiable any
longer to withhold peripheral decentralized epilepsy care
in rural areas on the grounds that there are not enough
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neurologists, or that facilities for investigations are ab-
sent. A clinical approach as outlined should suffice now
in a vast majority for rural epilepsy control in its early
stages. One need not wait for eons to come and deliver us
to eternal bliss and happiness!
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